Baricitinib: a new oral treatment for rheumatoid arthritis

Chaplin, Steve

doi:10.1002/psb.1586

Cited by 9 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, it is important to remember that type I IFN production is one of the initial and pivotal responses of the innate immunity against viral replication, especially in the earliest stages of infection [ 100 ]. Since type I IFN signaling depends on the JAK/STAT pathway via JAK1, baricitinib treatment might somehow reduce the type I IFN-mediated antiviral response [ 101 , 102 ].…”

Section: Therapymentioning

confidence: 99%

The Rheumatology Drugs for COVID-19 Management: Which and When?

Atzeni

Masala

Rodríguez‐Carrio

et al. 2021

JCM

View full text Add to dashboard Cite

Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-α, which hallmarks the most severe clinical cases. ‘Repurposing’ immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients.

show abstract

Section: Therapymentioning

confidence: 99%

The Rheumatology Drugs for COVID-19 Management: Which and When?

Atzeni

Masala

Rodríguez‐Carrio

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Four phases III trials demonstrate the key evidence for baricitinib: RA‐BEACON, RA‐BUILD, RA‐BEGIN and RA‐BEAM (Chaplin, 2017). The RA‐BEACON study in RA patients demonstrated significant improvements in physical function or other patient‐reported outcomes (PROs) in the cases who had been failed by previous treatment to biological disease‐modifying antirheumatic drugs (DMARDs; Genovese, Kremer, Kartman, et al, 2018; Smolen et al, 2016).…”

Section: Clinical Developmentsmentioning

confidence: 99%

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

Hosseini

Gharibi

Marofi

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Many cytokines are crucial drivers of cancers and autoimmune conditions. These proteins bind to receptors and signal their responses through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Genetic variations in the JAK-STAT pathway are correlated with the increased risk of cancers, autoimmunity as well as inflammatory diseases. Targeting JAKs and STATs can be a safe and efficacious strategy for treating these diseases. Tofacitinib, as the first JAK inhibitor, is approved for rheumatoid arthritis therapy. Also, many other JAK inhibitors have been proven or are in various phases of clinical trials for various diseases. At present, small-molecule JAK inhibitors are considered as a novel category of drugs in the treatment of cancer and immune-mediated diseases. K E Y W O R D S autoimmune diseases, cancer, Janus kinase inhibitors, novel treatment strategy

show abstract

“…14 Initiation of Baricitinib therapy may further reduce these counts. 9 Elevations of Creatine Kinase was observed in patients with Baricitinib therapy. 15 Although the median value of creatine kinase is reported to be in the normal range (<175U/L), it is greatly increased in the critically ill patients and non survivors.…”

mentioning

confidence: 99%

“…Similarly, it cannot be initiated in patients with an absolute lymphocyte count less than 0.5x10 9 cells/L. 9 In the epidemiological studies being carried out the values of the selected patients are closer to the threshold levels in the baseline. 10,11,12,13,14 (Table 1).…”

mentioning

confidence: 99%